RxDoctor Payments Data

Mary Price, MD

Ophthalmology · Wilmington, NCNPI 1821107772

Payments from drug & device makers

$3,431in general payments, 2019–2025

Across 177 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$973
  • Bausch & Lomb Americas Inc.$499
  • Sun Pharmaceutical Industries Inc.$492
  • Aerie Pharmaceuticals, Inc.$282
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$265
  • Alcon$170
  • plus $749 from 11 others

What the payments were for

  • Food & beverage$3,41299%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,431 in reported general payments places this provider in the 70th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$353,954
Medicare patients
822
Services billed
3,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost227$126,272
CombiganBrimonidine Tartrate/Timolol137$50,586
RestasisCyclosporine32$46,986
SimbrinzaBrinzolamide/Brimonidine Tart134$42,268
RhopressaNetarsudil Mesylate86$39,306
VyzultaLatanoprostene Bunod61$33,264
Travoprost105$24,174
RocklatanNetarsudil Mesylat/Latanoprost43$21,637
Dorzolamide Hcl933$20,526
Alphagan PBrimonidine Tartrate39$20,236
CequaCyclosporine15$19,526
TyrvayaVarenicline Tartrate28$18,968
Brimonidine Tartrate856$17,059
Latanoprost1,102$15,226
TafluprostTafluprost/Pf41$14,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$973$244,081435 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$282$60,943129 claims
AlconSimbrinza$170$42,268134 claims
Bausch & Lomb Americas Inc.Vyzulta$499$33,26461 claims
Sun Pharmaceutical Industries Inc.Cequa$492$19,52615 claims
Oyster Point Pharma, Inc.Tyrvaya$101$18,96828 claims
Thea Pharma Inc.Iyuzeh$58$10,88421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →